Published by Josh White on 27th February 2023
(Sharecast News) - Hutchmed China announced the completion of patient enrollment in a phase two registration trial of 'amdizalisib' on Monday, for the treatment of relapsed or refractory follicular lymphoma (FL), which is a subtype of non-Hodgkin's lymphoma.
URL: http://www.digitallook.com/dl/news/story/33331266/...